Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
Canada
0
South Africa
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)-1-pyrrolidinyl)-n-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide
2. Stendra
1. 330784-47-9
2. Stendra
3. Spedra
4. Ta 1790
5. Ta-1790
6. (s)-4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
7. Chebi:66876
8. Dr5s136ivo
9. (s)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[(2-pyrimidinylmethyl)carbamoyl]pyrimidine
10. (s)-4-(3-chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-n-pyrimidin-2-ylmethyl-5-pyrimidinecarboxamide
11. (s)-4-[(3-chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-n-(2pyrimidinylmethyl)-5-pyrimidinecarboxamide
12. 4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
13. 4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
14. 4-((3-chloro-4-methoxybenzyl)amino)-2-((2s)-2-(hydroxymethyl)pyrrolidin-1-yl)-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
15. 5-pyrimidinecarboxamide, 4-(((3-chloro-4-methoxyphenyl)methyl)amino)-2-((2s)-2-(hydroxymethyl)-1-pyrrolidinyl)-n-(2-pyrimidinylmethyl)-
16. Stendra (tn)
17. Avanafil [usan:inn]
18. Unii-dr5s136ivo
19. Zepeed
20. Ine-5-carboxamide
21. Spedra (tn)
22. Avanafil [usan]
23. Avanafil (usan/inn)
24. Avanafil [inn]
25. Avanafil [mi]
26. Avanafil [vandf]
27. Avanafil [mart.]
28. Avanafil [who-dd]
29. Avanafil 100 Microg/ml In Acetonitrile:dimethylsulfoxide
30. Schembl118799
31. Avanafil [orange Book]
32. Gtpl7448
33. Chembl1963681
34. Amy1794
35. Dtxsid50186727
36. 4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)-1-pyrrolidinyl)-n-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide
37. Bdbm50036629
38. Cs1566
39. Mfcd11977961
40. S4019
41. Ta1790
42. Zinc11677857
43. Akos024462448
44. Ccg-229896
45. Db06237
46. Vi-0162
47. Ncgc00386241-01
48. As-20106
49. Hy-18252
50. Sw219217-1
51. D03217
52. Ab01565827_02
53. J-019006
54. Q2873270
55. Brd-k65781196-001-01-4
56. (s)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[n-(2-pyrimidylmethyl)carbamoyl]-pyrimidine
57. (s)-4-[(3-chlor-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1- Pyrrolidinyl]-n-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamid
58. 4-[(3-chloranyl-4-methoxy-phenyl)methylamino]-2-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-n-(pyrimidin-2-ylmethyl)pyrimid
59. 4-[(3-chloranyl-4-methoxy-phenyl)methylamino]-2-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-n-(pyrimidin-2-ylmethyl)pyrimid Ine-5-carboxamide
60. Avanafil; (s)-4-chloro-6-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-n-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
61. E6l
Molecular Weight | 483.9 g/mol |
---|---|
Molecular Formula | C23H26ClN7O3 |
XLogP3 | 2.6 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 9 |
Exact Mass | 483.1785654 g/mol |
Monoisotopic Mass | 483.1785654 g/mol |
Topological Polar Surface Area | 125 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 642 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Stendra |
PubMed Health | Avanafil (By mouth) |
Drug Classes | Erectile Dysfunction Agent |
Drug Label | STENDRA (avanafil) is a selective inhibitor of cGMP-specific PDE5.Avanafil is designated chemically as (S)-4-[(3-Chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide and has the following... |
Active Ingredient | Avanafil |
Dosage Form | Tablet |
Route | Oral |
Strength | 200mg; 100mg; 50mg |
Market Status | Prescription |
Company | Vivus |
2 of 2 | |
---|---|
Drug Name | Stendra |
PubMed Health | Avanafil (By mouth) |
Drug Classes | Erectile Dysfunction Agent |
Drug Label | STENDRA (avanafil) is a selective inhibitor of cGMP-specific PDE5.Avanafil is designated chemically as (S)-4-[(3-Chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide and has the following... |
Active Ingredient | Avanafil |
Dosage Form | Tablet |
Route | Oral |
Strength | 200mg; 100mg; 50mg |
Market Status | Prescription |
Company | Vivus |
Avanafil is indicated for the treatment of erectile dysfunction.
FDA Label
Treatment of erectile dysfunction in adult men.
In order for Spedra to be effective, sexual stimulation is required.
Avanafil is a strong competitive inhibitor of phosphodiesterase 5 (PDE5) with a demonstrated _in vitro_ IC50 of 5.2 nM. Its inhibitory effects on PDE5 are 100-fold more potent than on PDE6 and >1000-fold more potent than on other PDE enzymes, meaning it is less likely to cause visual disturbances and cardiovascular adverse effects when compared with less selective PDE5 inhibitors such as [sildenafil] and [vardenafil]. It has a relatively quick onset of action allowing for administration as early as 15 minutes prior to sexual activity. PDE5 inhibitors like avanafil can cause significant drug interactions when administered alongside certain antihypertensive agents (e.g. alpha blockers, substantial amounts of alcohol). PDE5 inhibitors have also been associated with the development of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that typically presents as sudden loss of vision in one or both eyes and appears to be more common in patients with a "crowded" optic disc. Patients presenting with any degree of vision loss should immediately discontinue use of all PDE5 inhibitors and seek medical attention. In some jurisdictions, a history of NAION or other degenerative retinal disorders is considered a contraindication to avanafil therapy.
G04BE10
G04BE10
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
G - Genito urinary system and sex hormones
G04 - Urologicals
G04B - Urologicals
G04BE - Drugs used in erectile dysfunction
G04BE10 - Avanafil
Absorption
Avanafil is rapidly absorbed following oral administration (Tmax of 30-45 minutes) and appears to have low to moderate oral bioavailability, though formal studies have not been conducted. Administration with a meal results in a mean delay in Tmax of 1.12 to 1.25 hours, a 39% mean reduction in Cmax, and a negligible effect on AUC.
Route of Elimination
Following oral administration, avanafil is extensively metabolized. Approximately 62% of a given dose is excreted as metabolites in the feces and approximately 21% as metabolites in the urine.
Volume of Distribution
The apparent volume of distribution of avanafil is 47 to 83 L.
Avanafil is extensively metabolized, primarily by CYP3A4 and to a lesser extent by CYP2C9. There are two major metabolites formed, M4 and M16, which exist in the plasma at concentrations 23% and 29% that of the parent compound, respectively. The M16 metabolite lacks pharmacologic effect, but the M4 metabolite has an inhibitory potency for PDE5 18% that of avanafil and accounts for approximately 4% of the observed pharmacologic activity of avanafil.
Studies have demonstrated variability in the terminal elimination half-life of avanafil, with estimates ranging between 5 - 17 hours.
Avanafil inhibits the cGMP-specific phosphodiesterase type 5 (PDE5) which is responsible for the degradation of cGMP in the corpus cavernosum located around the penis. Sexual arousal results in the local release of nitric oxide, which in turn stimulates the enzyme guanylate cyclase to produce cGMP. Elevated levels of cGMP result in local smooth muscle relaxation and increased blood flow to the penis (i.e. an erection). As PDE5 inhibitors like avanafil require the endogenous release of nitric oxide in order to exert their pharmacologic effect, they have no effect on the user in the absence of sexual stimulation/arousal.
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29689
Submission : 2015-08-20
Status : Active
Type : II
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28732
Submission : 2014-10-07
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Century has been an API manufacturer for over 30 years & is the partner of choice for multipurpose custom manufacturing projects.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36175
Submission : 2021-09-16
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-02-05
Pay. Date : 2015-12-03
DMF Number : 30024
Submission : 2015-12-15
Status : Active
Type : II
NDC Package Code : 69037-0019
Start Marketing Date : 2012-04-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-12-16
Pay. Date : 2015-09-29
DMF Number : 28095
Submission : 2014-03-27
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-07-14
Written Confirmation Number : WC-0021n
Address of the Firm :
NDC Package Code : 14501-0090
Start Marketing Date : 2014-03-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24849
Submission : 2011-05-19
Status : Active
Type : II
Date of Issue : 2019-07-15
Valid Till : 2022-07-14
Written Confirmation Number : WC-0021
Address of the Firm :
NDC Package Code : 14501-0090
Start Marketing Date : 2014-03-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2022-06-17
Valid Till : 2025-07-14
Written Confirmation Number : WC-0021n
Address of the Firm : Sy. Nos: 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Man...
Date of Issue : 2019-07-15
Valid Till : 2022-07-14
Written Confirmation Number : WC-0021
Address of the Firm : Sy. No.317&323, Rudraram Village, Patancheru Mandal, Sangaredy District-502329 T...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Century has been an API manufacturer for over 30 years & is the partner of choice for multipurpose custom manufacturing projects.
About the Company : Century Pharmaceuticals, established in 1982, has 40 years of experience in manufacturing APIs. It has been supplying APIs produced in-house to several major pharma companies in In...
About the Company : Bajaj Healthcare Ltd. is a company established in 1993, services various Pharmaceuticals, Nutraceutical and Food industries globally with a spirit of scrupulousness. Bajaj Healt...
About the Company : In the dinamic pharmaceutical field, DEAFARMA is the reference point for primaries Pharmaceutical Laboratories for over twenty years, even in the national and international territo...
About the Company : Globofarm International Pvt Ltd is a well-informed, highly efficient, Swiftly functioning competitive sourcing entity. We serve private, institutional, and corporate clients worldw...
About the Company : Gokulendu Life Science offers broad portfolio of Active Pharmaceutical Ingredients (API). We began producing Active Pharmaceutical Ingredients (APIs) in 2020 as a vital input to ...
About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...
About the Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and chemical products, cat...
About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...
About the Company : Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Sweden
Brand Name : Spedra
Dosage Form : TABLET
Dosage Strength : 50 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Spedra
Dosage Form : TABLET
Dosage Strength : 100 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Spedra
Dosage Form : TABLET
Dosage Strength : 200 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Edra
Dosage Form : Avanafil 100Mg 12 Combined Oral Use
Dosage Strength : 12 CPR 100 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Edra
Dosage Form : Avanafil 200Mg 12 Combined Oral Use
Dosage Strength : 12 CPR 200 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Avanafil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Avanafil, including repackagers and relabelers. The FDA regulates Avanafil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Avanafil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Avanafil manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Avanafil supplier is an individual or a company that provides Avanafil active pharmaceutical ingredient (API) or Avanafil finished formulations upon request. The Avanafil suppliers may include Avanafil API manufacturers, exporters, distributors and traders.
click here to find a list of Avanafil suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Avanafil DMF (Drug Master File) is a document detailing the whole manufacturing process of Avanafil active pharmaceutical ingredient (API) in detail. Different forms of Avanafil DMFs exist exist since differing nations have different regulations, such as Avanafil USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Avanafil DMF submitted to regulatory agencies in the US is known as a USDMF. Avanafil USDMF includes data on Avanafil's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Avanafil USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Avanafil suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Avanafil Drug Master File in Korea (Avanafil KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Avanafil. The MFDS reviews the Avanafil KDMF as part of the drug registration process and uses the information provided in the Avanafil KDMF to evaluate the safety and efficacy of the drug.
After submitting a Avanafil KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Avanafil API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Avanafil suppliers with KDMF on PharmaCompass.
A Avanafil written confirmation (Avanafil WC) is an official document issued by a regulatory agency to a Avanafil manufacturer, verifying that the manufacturing facility of a Avanafil active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Avanafil APIs or Avanafil finished pharmaceutical products to another nation, regulatory agencies frequently require a Avanafil WC (written confirmation) as part of the regulatory process.
click here to find a list of Avanafil suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Avanafil as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Avanafil API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Avanafil as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Avanafil and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Avanafil NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Avanafil suppliers with NDC on PharmaCompass.
Avanafil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Avanafil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Avanafil GMP manufacturer or Avanafil GMP API supplier for your needs.
A Avanafil CoA (Certificate of Analysis) is a formal document that attests to Avanafil's compliance with Avanafil specifications and serves as a tool for batch-level quality control.
Avanafil CoA mostly includes findings from lab analyses of a specific batch. For each Avanafil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Avanafil may be tested according to a variety of international standards, such as European Pharmacopoeia (Avanafil EP), Avanafil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Avanafil USP).
LOOKING FOR A SUPPLIER?